{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:37:00Z","timestamp":1769168220702,"version":"3.49.0"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>The management of brain metastases is increasingly complex and requires multidisciplinary input from a wide array of experts, including radiation oncology, medical oncology, neurosurgery, and palliative care. Novel radiation techniques, radiosensitization, combination approaches with systemic therapy and approaches to penetrate or bypass the blood-brain barrier represent some of the more promising strategies that have the potential to improve outcomes of brain metastases patients. A better understanding of the biology and development of brain metastases may allow for greater efforts towards prevention. Rigorous, well-designed clinical trials addressing specific challenges of the brain metastasis population will be necessary to evaluate these novel approaches.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000807","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:00:26Z","timestamp":1769112026000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Future Directions and Emerging Approaches in the Treatment of Brain Metastases"],"prefix":"10.1097","volume":"32","author":[{"given":"Rifaquat","family":"Rahman","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minesh","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Baptist Health, Miami Cancer Institute, Florida International University, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,1]]},"reference":[{"key":"R1-20260122","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"R2-20260122","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/neuonc\/noac118","article-title":"Brain metastases: a Society for Neuro-Oncology (SNO) consensus review on current management and future directions","volume":"24","author":"Aizer","year":"2022","journal-title":"Neuro Oncol"},{"key":"R3-20260122","doi-asserted-by":"crossref","first-page":"e433694","DOI":"10.1200\/EDBK_433694","article-title":"Navigating the complexities of brain metastases management","volume":"44","author":"Amouzegar","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R4-20260122","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III Trial NRG Oncology CC001","volume":"38","author":"Brown","year":"2020","journal-title":"JCO"},{"key":"R5-20260122","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/neuonc\/not114","article-title":"Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Brown","year":"2013","journal-title":"Neuro Oncol"},{"key":"R6-20260122","doi-asserted-by":"crossref","first-page":"1298605","DOI":"10.3389\/fonc.2024.1298605","article-title":"Unilateral hippocampal sparing during whole brain radiotherapy for multiple brain metastases: narrative and critical review","volume":"14","author":"Pospisil","year":"2024","journal-title":"Front Oncol"},{"key":"R7-20260122","doi-asserted-by":"crossref","first-page":"101337","DOI":"10.1016\/j.adro.2023.101337","article-title":"Advancing beyond the hippocampus to preserve cognition for patients with brain metastases: dosimetric results from a phase 2 trial of memory-avoidance whole brain radiation therapy","volume":"9","author":"Perlow","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"R8-20260122","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"},{"key":"R10-20260122","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/neuonc\/noae049","article-title":"Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: a report of the PET\/RANO group","volume":"26","author":"Galldiks","year":"2024","journal-title":"Neuro Oncol"},{"key":"R11-20260122","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41698-024-00575-0","article-title":"Artificial intelligence in neuro-oncology: advances and challenges in brain tumor diagnosis, prognosis, and precision treatment","volume":"8","author":"Khalighi","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"R12-20260122","doi-asserted-by":"crossref","first-page":"601820","DOI":"10.3389\/fonc.2021.601820","article-title":"Boron neutron capture therapy: a review of clinical applications","volume":"11","author":"Malouff","year":"2021","journal-title":"Front Oncol"},{"key":"R13-20260122","doi-asserted-by":"crossref","first-page":"nwae350","DOI":"10.1093\/nsr\/nwae350","article-title":"Current views on mechanisms of the FLASH effect in cancer radiotherapy","volume":"11","author":"Ma","year":"2024","journal-title":"Nation Sci Rev"},{"key":"R14-20260122","doi-asserted-by":"crossref","first-page":"10943","DOI":"10.1073\/pnas.1901777116","article-title":"Long-term neurocognitive benefits of FLASH radiotherapy driven by reduced reactive oxygen species","volume":"116","author":"Montay-Gruel","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-20260122","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3390\/cancers13050936","article-title":"Unexpected benefits of multiport synchrotron microbeam radiation therapy for brain tumors","volume":"13","author":"Eling","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"supplement_9","key":"R16-20260122","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1093\/neuonc\/noae192","article-title":"Targeted radionuclide therapy for patients with central nervous system metastasis: Overlooked potential?","volume":"26","author":"Le Rhun","year":"2024","journal-title":"Neuro Oncol"},{"key":"R17-20260122","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0360-3016(90)90489-7","article-title":"90Y.B72.3 against pancreatic cancer: dosimetric and biological analysis","volume":"19","author":"Mehta","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R18-20260122","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"R19-20260122","first-page":"e45327","article-title":"Definitive treatment of brain metastases from a neuroendocrine tumor with peptide receptor radionuclide therapy with 177Lutetium DOTATATE: a case report","volume":"15","author":"Zhang","year":"2023","journal-title":"Cureus"},{"key":"R20-20260122","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11102-007-0038-6","article-title":"Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review","volume":"11","author":"Goglia","year":"2008","journal-title":"Pituitary"},{"key":"R21-20260122","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.ijrobp.2024.07.003","article-title":"A prospective, phase II study of 177Lu-dotatate in patients with surgery- and radiation-refractory meningioma: results of the WHO Grade II\/III cohort","volume":"120","author":"Merrell","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R22-20260122","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-23-2533","article-title":"Evaluation of the SSTR2-targeted radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as imaging biomarker in patients with intracranial meningioma","volume":"30","author":"Kurz","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R23-20260122","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13014-017-0774-3","article-title":"Clinical outcomes of gastrointestinal brain metastases treated with radiotherapy","volume":"12","author":"Sanghvi","year":"2017","journal-title":"Radiat Oncol"},{"key":"R24-20260122","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10549-019-05236-6","article-title":"Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases","volume":"176","author":"Cagney","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"R25-20260122","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11060-019-03106-1","article-title":"Local control after brain-directed radiation in patients with cystic versus solid brain metastases","volume":"142","author":"Brigell","year":"2019","journal-title":"J Neurooncol"},{"key":"R26-20260122","doi-asserted-by":"crossref","first-page":"173sr2","DOI":"10.1126\/scitranslmed.3005148","article-title":"New paradigms and future challenges in radiation oncology: an update of biological targets and technology","volume":"5","author":"Liauw","year":"2013","journal-title":"Sci Transl Med"},{"key":"R27-20260122","doi-asserted-by":"crossref","first-page":"e2318119121","DOI":"10.1073\/pnas.2318119121","article-title":"Simultaneous targeting of peripheral and brain tumors with a therapeutic nanoparticle to disrupt metabolic adaptability at both sites","volume":"121","author":"Ashokan","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R28-20260122","doi-asserted-by":"crossref","first-page":"633827","DOI":"10.3389\/fonc.2021.633827","article-title":"Application of new radiosensitizer based on nano-biotechnology in the treatment of glioma","volume":"11","author":"Xie","year":"2021","journal-title":"Front Oncol"},{"key":"R29-20260122","doi-asserted-by":"crossref","first-page":"124301","DOI":"10.1016\/j.ijpharm.2024.124301","article-title":"A recent insight of applications of gold nanoparticles in glioblastoma multiforme therapy","volume":"660","author":"Qureshi","year":"2024","journal-title":"Int J Pharm"},{"key":"R30-20260122","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3390\/ma17051153","article-title":"Designing gold nanoparticles for precise glioma treatment: challenges and alternatives","volume":"17","author":"Lansangan","year":"2024","journal-title":"Materials (Basel)"},{"key":"R31-20260122","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3390\/ph18040519","article-title":"Mechanisms of action of AGuIX as a pan-cancer nano-radiosensitizer: a comprehensive review","volume":"18","author":"Aubrun","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"R32-20260122","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2021.04.021","article-title":"Theranostic AGuIX nanoparticles as radiosensitizer: a phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial)","volume":"160","author":"Verry","year":"2021","journal-title":"Radiother Oncol"},{"key":"R33-20260122","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/neuonc\/noae072","article-title":"DNA damage response in brain tumors: a Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology","volume":"26","author":"Rahman","year":"2024","journal-title":"Neuro Oncol"},{"key":"R34-20260122","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1038\/s41467-024-49316-8","article-title":"ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma","volume":"15","author":"Laverty","year":"2024","journal-title":"Nat Commun"},{"key":"R35-20260122","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1158\/1535-7163.MCT-21-0305","article-title":"ATR inhibitor M6620 (VX-970) enhances the effect of radiation in non-small cell lung cancer brain metastasis patient-derived xenografts","volume":"20","author":"Baschnagel","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"R36-20260122","doi-asserted-by":"crossref","first-page":"1477448","DOI":"10.3389\/fonc.2024.1477448","article-title":"Radioresistance and brain metastases: a review of the literature and applied perspective","volume":"14","author":"Youssef","year":"2024","journal-title":"Front Oncol"},{"key":"R37-20260122","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41591-022-01749-8","article-title":"Stratification of radiosensitive brain metastases based on an actionable S100A9\/RAGE resistance mechanism","volume":"28","author":"Monteiro","year":"2022","journal-title":"Nat Med"},{"issue":"suppl","key":"R38-20260122","doi-asserted-by":"crossref","first-page":"TPS2093","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2093","article-title":"A phase I\/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION)","volume":"42","author":"Kotecha","year":"2024","journal-title":"JCO"},{"key":"R39-20260122","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/neuonc\/noad098","article-title":"A genomic score to predict local control among patients with brain metastases managed with radiation","volume":"25","author":"Lamba","year":"2023","journal-title":"Neuro Oncol"},{"key":"R40-20260122","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3390\/cancers17091591","article-title":"Exploring the role of ADCs in brain metastases and primary brain tumors: insight and future directions","volume":"17","author":"Bruzzone","year":"2025","journal-title":"Cancers (Basel)"},{"key":"R41-20260122","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3390\/cancers13102391","article-title":"Breaching the blood-brain tumor barrier for tumor therapy","volume":"13","author":"Marcucci","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R42-20260122","doi-asserted-by":"crossref","first-page":"102924","DOI":"10.1016\/j.esmoop.2024.102924","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial","volume":"9","author":"Hurvitz","year":"2024","journal-title":"ESMO Open"},{"key":"R43-20260122","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/neuonc\/noae123","article-title":"Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases","volume":"26","author":"Bartsch","year":"2024","journal-title":"Neuro Oncol"},{"key":"R44-20260122","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.1038\/s41467-024-50558-9","article-title":"Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial","volume":"15","author":"Balinda","year":"2024","journal-title":"Nat Commun"},{"key":"R47-20260122","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jamaoncol.2023.4492","article-title":"Symptomatic necrosis with antibody-drug conjugates and concurrent stereotactic radiotherapy for brain metastases","volume":"9","author":"Lebow","year":"2023","journal-title":"JAMA Oncol"},{"key":"R48-20260122","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/neuonc\/not329","article-title":"Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema","volume":"16","author":"Carlson","year":"2014","journal-title":"Neuro Oncol"},{"key":"R49-20260122","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3390\/cells12101398","article-title":"Next-generation boron drugs and rational translational studies driving the revival of BNCT","volume":"12","author":"Seneviratne","year":"2023","journal-title":"Cells"},{"key":"R50-20260122","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11060-024-04754-8","article-title":"Patterns of brain metastases response to immunotherapy with pembrolizumab","volume":"169","author":"Mahajan","year":"2024","journal-title":"J Neurooncol"},{"key":"R51-20260122","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"R52-20260122","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"R53-20260122","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-025-00812-0","article-title":"Progress in personalized immunotherapy for patients with brain metastasis","volume":"9","author":"Patel","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"R54-20260122","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"key":"R55-20260122","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1078-0432.CCR-23-1735","article-title":"Intratumoral delivery of chimeric antigen receptor t cells targeting CD133 effectively treats brain metastases","volume":"30","author":"Kieliszek","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R56-20260122","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/s41467-022-29647-0","article-title":"Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"R57-20260122","doi-asserted-by":"crossref","first-page":"1517348","DOI":"10.3389\/fimmu.2025.1517348","article-title":"Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas","volume":"16","author":"Manzar","year":"2025","journal-title":"Front Immunol [Internet]"},{"key":"R58-20260122","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2021.11.031","article-title":"Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?","volume":"166","author":"Saifi","year":"2022","journal-title":"Radiother Oncol"},{"key":"R59-20260122","doi-asserted-by":"crossref","first-page":"12654","DOI":"10.3390\/ijms222312654","article-title":"Blood-brain barrier in brain tumors: biology and clinical relevance","volume":"22","author":"Mo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R60-20260122","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11060-023-04492-3","article-title":"Focused ultrasound for brain metastases: an update on global clinical trials","volume":"165","author":"Chen","year":"2023","journal-title":"J Neurooncol"},{"key":"R61-20260122","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jconrel.2014.06.031","article-title":"Non-invasive delivery of stealth, brain-penetrating nanoparticles across the blood-brain barrier using MRI-guided focused ultrasound","volume":"189","author":"Nance","year":"2014","journal-title":"J Control Release"},{"key":"R62-20260122","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jconrel.2012.09.007","article-title":"Ultrasound-mediated blood-brain\/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model","volume":"163","author":"Park","year":"2012","journal-title":"J Control Release"},{"issue":"suppl","key":"R63-20260122","first-page":"TPS2089","article-title":"A multicenter, randomized, controlled, pivotal trial of microbubble-enhanced transcranial focused ultrasound for patients with NSCLC brain metastases (LIMITLESS)","volume":"43","author":"Ahluwalia","year":"2025","journal-title":"JCO"},{"key":"R64-20260122","doi-asserted-by":"crossref","first-page":"oyae227","DOI":"10.1093\/oncolo\/oyae227","article-title":"Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma","volume":"30","author":"Khagi","year":"2025","journal-title":"Oncologist"},{"key":"R65-20260122","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"R66-20260122","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur J Cancer"},{"issue":"suppl","key":"R67-20260122","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2024.42.16_suppl.2008","article-title":"Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases","volume":"42","author":"Mehta","year":"2024","journal-title":"JCO"},{"key":"R69-20260122","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11060-023-04541-x","article-title":"The role of microRNAs in brain metastasis","volume":"166","author":"Hudson","year":"2024","journal-title":"J Neurooncol"},{"key":"R70-20260122","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"key":"R71-20260122","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/j.cell.2022.06.007","article-title":"Dissecting the treatment-naive ecosystem of human melanoma brain metastasis","volume":"185","author":"Biermann","year":"2022","journal-title":"Cell"},{"key":"R72-20260122","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41591-024-03286-y","article-title":"Prediction of brain metastasis development with DNA methylation signatures","volume":"31","author":"Zuccato","year":"2025","journal-title":"Nat Med"},{"key":"R73-20260122","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-019-1576-6","article-title":"Synaptic proximity enables NMDAR signalling to promote brain metastasis","volume":"573","author":"Zeng","year":"2019","journal-title":"Nature"},{"key":"R75-20260122","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/neuonc\/noab290","article-title":"Neuronal exposure induces neurotransmitter signaling and synaptic mediators in tumors early in brain metastasis","volume":"24","author":"Deshpande","year":"2022","journal-title":"Neuro Oncol"},{"key":"R76-20260122","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa071780","article-title":"Prophylactic cranial irradiation in extensive small-cell lung cancer","volume":"357","author":"Slotman","year":"2007","journal-title":"N Engl J Med"},{"key":"R77-20260122","doi-asserted-by":"crossref","first-page":"102860","DOI":"10.1016\/j.ctrv.2024.102860","article-title":"Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer","volume":"132","author":"M\u00fcller","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"R78-20260122","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3390\/cancers16112134","article-title":"Prevention of brain metastases: a new frontier","volume":"16","author":"Pellerino","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R79-20260122","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41392-022-00872-9","article-title":"Targeting polarized phenotype of microglia via IL6\/JAK2\/STAT3 signaling to reduce NSCLC brain metastasis","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"R80-20260122","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(23)00005-0","article-title":"Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference","volume":"24","author":"Rahman","year":"2023","journal-title":"Lancet Oncol"},{"key":"R82-20260122","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"R83-20260122","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S1470-2045(17)30692-7","article-title":"Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group","volume":"19","author":"Alexander","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:00:35Z","timestamp":1769112035000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000807","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-07-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}